NASDAQ:BBIO BridgeBio Pharma (BBIO) Stock Price, News & Analysis $78.30 +0.13 (+0.17%) Closing price 11/13/2026 04:00 PM EasternExtended Trading$78.30 0.00 (-0.01%) As of 11/13/2026 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About BridgeBio Pharma Stock (NASDAQ:BBIO) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BridgeBio Pharma alerts:Sign Up Key Stats Today's Range$77.58▼$79.1350-Day Range$63.30▼$79.5452-Week Range$62.50▼$93.42Volume1.15 million shsAverage Volume3.06 million shsMarket Capitalization$15.25 billionP/E RatioN/ADividend YieldN/APrice Target$104.42Consensus RatingModerate Buy Company Overview BridgeBio Pharma is a biopharmaceutical company that discovers, develops and commercializes medicines for genetic diseases and cancers. Founded in 2015, the company advances programs through a network of research and development subsidiaries focused on specific conditions and therapeutic areas. Its products include Attruby (acoramidis), an FDA-approved treatment for adults with transthyretin amyloid cardiomyopathy. BridgeBio also develops a pipeline of investigational therapies aimed at diseases with well-understood genetic causes, including rare and inherited conditions. BridgeBio is headquartered in Palo Alto, California. Co-founder Neil Kumar serves as the company’s chief executive officer.AI Generated. May Contain Errors. Read More BridgeBio Pharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks71st Percentile Overall ScoreBBIO MarketRank™: 3.551255230125 of 5 starsBridgeBio Pharma scored higher than 71% of companies evaluated by MarketBeat, and ranked 213th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingBridgeBio Pharma has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on no strong buy ratings, 19 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialBridgeBio Pharma has a consensus price target of $104.42, representing about 33.4% upside from its current price of $78.30.Amount of Analyst CoverageBridgeBio Pharma has been the subject of 12 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BridgeBio Pharma's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BridgeBio Pharma are expected to grow in the coming year, from ($2.55) to ($0.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BridgeBio Pharma is -25.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BridgeBio Pharma is -25.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted12.48% of the float of BridgeBio Pharma has been sold short.Short Interest Ratio / Days to CoverBridgeBio Pharma has a short interest ratio ("days to cover") of 7.06.Change versus previous monthShort interest in BridgeBio Pharma has recently increased by 4.24%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBridgeBio Pharma does not currently pay a dividend.Dividend GrowthBridgeBio Pharma does not have a long track record of dividend growth. News and Social Media3.8 / 5News Sentiment1.04 News SentimentBridgeBio Pharma has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 13 news articles for BridgeBio Pharma this week, compared to 9 articles on an average week.Search Interest10 people have searched for BBIO on MarketBeat in the last 30 days. This is an increase of 43% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added BridgeBio Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, BridgeBio Pharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $4,563,699.00 in company stock.Percentage Held by Insiders14.23% of the stock of BridgeBio Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions99.85% of the stock of BridgeBio Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about BridgeBio Pharma's insider trading history. Receive BBIO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BridgeBio Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BBIO Stock News HeadlinesBridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock Has Consensus Price Target of $104.26 According to BrokeragesNovember 12 at 3:01 AM | americanbankingnews.comBridgeBio to Present New Acoramidis Data on Kidney Function, Real-World Outcomes, and First-Line Treatment Patterns in ATTR-CM at the International Symposium on Amyloidosis 2026November 11, 2026 | globenewswire.comToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one lesser known company. With plans filed for 1,000,000 new satellites, that licensing fee could scale dramatically. Analyst Dylan says the stock could move by December 8th. | Behind the Markets (Ad)BridgeBio to Participate in November and December Investor ConferencesNovember 9, 2026 | globenewswire.comBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)November 6, 2026 | globenewswire.comInsider Selling: BridgeBio Pharma (NASDAQ:BBIO) CAO Sells 2,000 Shares of Company StockNovember 4, 2026 | insidertrades.comBridgeBio Pharma (NASDAQ:BBIO) Stock Gets Price Target Increase from Canaccord Genuity GroupNovember 4, 2026 | americanbankingnews.comBarclays Keeps Their Buy Rating on BridgeBio Pharma (BBIO)November 3, 2026 | theglobeandmail.comSee More Headlines BBIO Stock Analysis - Frequently Asked Questions How have BBIO shares performed this year? BridgeBio Pharma's stock was trading at $76.49 at the beginning of the year. Since then, BBIO stock has increased by 2.4% and is now trading at $78.30. How were BridgeBio Pharma's earnings last quarter? BridgeBio Pharma, Inc. (NASDAQ:BBIO) released its quarterly earnings data on Thursday, October, 29th. The company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.54) by $0.12. The firm's quarterly revenue was up 192.6% on a year-over-year basis. Read the conference call transcript. When did BridgeBio Pharma IPO? BridgeBio Pharma (BBIO) raised $308 million in an initial public offering (IPO) on Thursday, June 27th 2019. The company issued 20,500,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs, Jefferies, SVB Leerink and KKR acted as the underwriters for the IPO and Piper Jaffray, Mizuho Securities, BMO Capital Markets and Raymond James were co-managers. Who are BridgeBio Pharma's major shareholders? BridgeBio Pharma's top institutional shareholders include Pictet Asset Management Holding SA (0.86%), GW&K Investment Management LLC (0.49%), Allspring Global Investments Holdings LLC (0.37%) and Candriam S.C.A. (0.36%). Insiders that own company stock include Global Investors Lp Viking, Genetic Disorder LP Kkr, Charles J Homcy, Frank Mccormick, Neil Kumar, Thomas Trimarchi, Maricel Apuli, Brian C Stephenson, Andrew Lo, Andrea Ellis, Ronald J Daniels, Randal W Scott, Hannah Valantine and Jennifer E Cook. View institutional ownership trends. How do I buy shares of BridgeBio Pharma? Shares of BBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BridgeBio Pharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that BridgeBio Pharma investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Micron Technology (MU), CrowdStrike (CRWD), Palantir Technologies (PLTR) and Alibaba Group (BABA). Company Calendar Last Earnings10/29/2026Today11/14/2026Jefferies Global Healthcare Conference11/16/20269th Annual Evercore ISI HealthCONx Conference11/30/2026Citi Annual Global Healthcare Conference 202612/01/202638th Annual Healthcare Conference12/02/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 2 weeks, BBIO's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BBIO CIK1743881 Webbridgebio.com Phone(650) 391-9740FaxN/AEmployees839Year Founded2014Price Target and Rating Average Price Target for BridgeBio Pharma$104.42 High Price Target$156.00 Low Price Target$81.00 Potential Upside/Downside+33.4%Consensus RatingModerate Buy Rating Score (0-4)2.82 Research Coverage22 Analysts Profitability EPS (Trailing Twelve Months)($3.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$724.93 million Net Margins-59.84% Pretax Margin-60.97% Return on EquityN/A Return on Assets-39.81% Debt Debt-to-Equity RatioN/A Current Ratio2.09 Quick Ratio2.03 Sales & Book Value Annual Sales$502.08 million Price / Sales30.38 Cash FlowN/A Price / Cash FlowN/A Book Value($13.32) per share Price / Book-5.88Miscellaneous Outstanding Shares194,800,000Free Float167,081,000Market Cap$15.25 billion OptionableOptionable Beta0.97 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:BBIO) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredDrop these 5 stocks before the market opens tomorrow!The Wall Street Journal called it the "$64 trillion question": is a stock market crash on the way? Weiss Ratin...Weiss Ratings | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BridgeBio Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BridgeBio Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
